From i3L to UCL: Immaculata Titis Winiati’s Journey in Digital Health
Monday, 20 January 2025 – We at i3L are proud to share the inspiring journey of Immaculata Titis Winiati (Titis), a 2015 graduate of i3L’s Biomedicine Bachelor program, who is currently pursuing a Master’s in Digital Health and Entrepreneurship at University College London (UCL) through the prestigious Chevening Scholarship.
Why UCL?
Drawn to UCL’s esteemed reputation in medical science and its innovative approach to digital health, Titis sought a program that blended academic rigor with real-world applications. The chosen program perfectly aligns with her passion for leveraging technology to improve patient outcomes. Furthermore, UCL’s diverse student body offered valuable opportunities for cross-disciplinary learning and collaboration.
Navigating the Application Process
Getting Accepted in one of the best universities in the world is surely not easy. The application process for both UCL and the Chevening Scholarship was rigorous. Key to success in the Chevening application was demonstrating strong leadership potential, a clear career vision, and a compelling plan for contributing to her community. The interview stage required meticulous preparation, focusing on effectively communicating her unique story, aspirations, and how the scholarship would facilitate her impact.
Post-Graduation Plans
Upon graduation, Titis plans to return to Indonesia and contribute to the nation’s healthcare sector. She aims to utilize her newfound knowledge by implementing digital health solutions, conducting impactful projects in various therapeutic areas, and providing valuable insights to monitor the transformative effects of digital health in Indonesia.
The Impact of i3L
We at i3L are pleased to see how our well-built curriculum has played a pivotal role in Titis’s academic journey. The program provided a strong foundation in life sciences, enabling a deeper understanding of complex health challenges. Moreover, we emphasize essential soft skills such as communication, critical thinking, and collaboration, which are invaluable in both academic and professional settings, and we are delighted to see these skills flourishing in Titis’s journey.
Tips to Securing Chevening Scholarship
For students aspiring to pursue a Master’s at UCL through the Chevening Scholarship, Titis offers the following advice:
Titis’s journey serves as an inspiration to all i3L students, demonstrating the transformative power of education and the potential to achieve great things. We at i3L are confident that Titis’s achievements will inspire future generations to pursue their academic and professional aspirations with dedication and determination. We wish all students the very best in their academic endeavors and hope to see everyone achieve their dreams, just as Titis has done
Learn Biomedicine at i3L
i3L’s Biomedicine program focuses on research and innovation that bridges the study on human health and disease with therapeutic and diagnostic development. Currently, our program offers three specialization streams that focus on tumor biology, infectious disease, and bioinformatics.
Streams
Courses
i3L’s Biomedicine Alumni
“i3L’s strong partnerships in academia and industrial research are highly valuable, opening many doors for internships, placements, and training for students. These opportunities help develop research skills as an undergraduate, which I have personally experienced. I am grateful to be a recipient of i3L’s full scholarship for four years, allowing me to focus on my studies and enjoy my time at i3L. It is no overstatement that i3L has significantly contributed to nurturing my interest in life sciences, research, and my decision to continue my studies now.”
Nurulfitri Wisetyaningsih
Alumna of Biomedicine 2015
Ph.D. Student, Clinical Medicine Research at National Heart and Lung Institute, Imperial College London
Jl. Pulomas Barat Kav 88, Jakarta Timur 13210, Indonesia.
+6221 295 67 888 (Admission & Customer Service)
+6221 295 67 899 (Operator)
© 2022 Indonesia International Institute for Life Sciences. All rights reserved.